Kumiai Chemical Industry Cuts Profit Forecast Despite Revenue Upgrade
Kumiai Chemical Industry Co., Ltd. (TSE:4996) has revised its full-year earnings forecast for the fiscal year ending October 2026, raising revenue guidance but significantly lowering profitability expectations due to generic competition in key herbicide markets and extraordinary losses.
| Item | Before | After | Change |
|---|---|---|---|
| Revenue | JPY 162.0bn | JPY 175.0bn | +8.0% |
| Operating Profit | JPY 7.20bn | JPY 2.70bn | -62.5% |
| Ordinary Income | JPY 10.9bn | JPY 8.50bn | -22.0% |
| Net Profit (attributable to parent) | JPY 6.40bn | JPY 4.00bn | -37.5% |
| EPS | JPY 53.15/share | JPY 33.20/share | -37.5% |
The company raised revenue guidance by JPY 13.0bn on stronger sales in its agrochemical and agricultural-related business and chemical products segments. However, operating profit plummeted 62.5% to JPY 2.70bn, primarily driven by inventory valuation losses stemming from price declines in its overseas herbicide product “Axeev” following generic market entry. The ordinary income (keijo rieki)—a Japan-specific metric encompassing operating profit plus non-operating items—declined 22.0% to JPY 8.50bn, partially cushioned by gains from equity-method investment income and foreign exchange benefits from yen weakness. Net profit attributable to parent shareholders fell 37.5% to JPY 4.00bn, reflecting additional extraordinary losses including fixed asset impairment charges and restructuring expenses.
The revision signals intensifying competitive pressures in key export markets and ongoing structural challenges within the company’s portfolio. While top-line growth demonstrates underlying demand strength, the sharp profitability contraction underscores margin compression from generic competition and one-time charges related to business restructuring. Investors should monitor management’s progress on cost mitigation and product portfolio optimization in coming quarters.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Always verify against the original filing.